Navigation Links
Medivir Interim Report, 1 January - 30 September 2010
Date:10/22/2010

lopment drug for Hepatitis C (HCV) infections. These data demonstrate that TMC435 has potent antiviral effect and an attractive safety profile, properties making TMC435 the best in class investigational HCV drug under development. - To realise the maximum commercial value in different markets, another two distribution partnering deals have been entered for Xerclear(R)/Xerese(R), an innovative treatment for cold sores, with Daewoong and Luxembourg. This is in addition to Medivir's agreement with GlaxoSmithKline for OTC sales in Europe and other key territories and the agreement with Meda for Rx sales in North America. During the ongoing preparations for this introduction to the market, the launch of Xerese(R) in North America has been confirmed for the first quarter of 2011. - The early-stage antiviral project portfolio, focusing on new approaches to treat HCV and other infectious diseases, is progressing well. Post Period End Highlights - Medivir announced in early October that new results with TMC435 will be presented at the American Association for the Study of Liver Diseases (AASLD) meeting in Boston in late October 2010. This will be via a late breaking oral presentation on TMC435 phase 2b ongoing studies and four additional poster presentations on data regarding efficacy and safety and pharmacokinetic data of TMC435.

A comment from Ron Long, Medivir's CEO:

"Medivir has continued to make important progress in the third quarter of this year on the route towards becoming a successful specialty pharmaceutical company operating on an international stage. Our lead development product, TMC435, has blockbuster potential in the exciting Hepatitis C therapy arena. TMC435 is demonstrating extremely positive data in phase 2b trials, with clear competitive advantages. We look forward to the presentation of week-24 interim results at the AASLD meeting in Boston in October.

We have also worked hard during this quarter to ensure that we increase the
'/>"/>

SOURCE Medivir AB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
3. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
4. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
5. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
6. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
7. Grantees of the Avon Foundation Breast Cancer Prevention Research Initiative Gather in Houston to Report Interim Findings
8. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
9. Interim Safety Analysis Supports Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
10. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
11. NanoBio Corporation Presents Preclinical and Interim Clinical Data on Topical Treatments for Herpes Labialis and Onychomycosis at AAD 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 29, 2014 McGraw-Hill Education Professional, a leading ... technical, and medical communities, has announced the launch of ... application of the world-renowned medical education platform. ... App , available for download onto all iOS and ... to gain access to valuable AccessMedicine diagnostic ...
(Date:7/29/2014)... 2014 According to a new ... Fixation Devices Market - Global Forecast, Market Share, Size, ... orthopedic trauma fixation devices market is estimated at USD ... at a CAGR of 7.2% from 2014 to 2019, ... in 2020. Browse the Orthopedic Trauma Fixation ...
(Date:7/29/2014)... , July 29, 2014  Instrumentation Laboratory (IL) today announced ... new corporate logo. This is part of a comprehensive rebranding ... Founded in Boston, MA , in 1959, ... companies since 1992.  Other companies in the group include Inova ... Systelab ( Barcelona, Spain ).  Like IL, these ...
Breaking Medicine Technology:McGraw-Hill Education Professional's AccessMedicine App Delivers Instant Access to Essential Diagnostic Tools 2McGraw-Hill Education Professional's AccessMedicine App Delivers Instant Access to Essential Diagnostic Tools 3Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 2Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 3Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 4Instrumentation Laboratory Unveils New Corporate Brand 2Instrumentation Laboratory Unveils New Corporate Brand 3
... SAN DIEGO, April 29, 2011 Halozyme Therapeutics, Inc. ... and commercializing products targeting the extracellular matrix , ... financial results on Friday, May 6, 2011 before the ... followed by a conference call with the investment community ...
... Pa., April 29, 2011 Inovio Pharmaceuticals, Inc. (NYSE Amex: ... therapeutic and preventive vaccines against cancers and infectious diseases, announced ... conferences: JMP Securities Research Conference San ... Inovio Presentation Dr. J. Joseph Kim, ...
Cached Medicine Technology:Halozyme Therapeutics to Host First Quarter 2011 Financial Results Conference Call on May 6 2Inovio Pharmaceuticals to Present at Investor Conferences 2Inovio Pharmaceuticals to Present at Investor Conferences 3Inovio Pharmaceuticals to Present at Investor Conferences 4
(Date:7/29/2014)... 2014 Many people complain about their dependence ... each morning is put on glasses to see their clock ... individuals also may be dissatisfied with their vision even when ... may cause difficulty driving, especially at night due to glare. ... one’s golf ball, see the TV, sew or cross stitch, ...
(Date:7/29/2014)... Alan Mozes HealthDay Reporter ... autism patients with just a single dose of the hormone ... emotions, Japanese researchers report. Known as the "love hormone," ... bonding between lovers, and between mothers and their children. ... key area of the brain that has long been associated ...
(Date:7/29/2014)... During his 37 years in dental practice, Dr. Arthur ... a steady stream of college students shadow him in order ... on to dental school and some are now practicing dentistry ... college students find success. , For students interested in applying ... to see a realistic view of what goes on in ...
(Date:7/29/2014)... headache sufferers to record the severity and regularity of ... Griffith research study. , A new approach to the ... with their triggers and is being led by Professor ... Health program. , He has developed an approach designed ... their headaches called Learning to Cope with Triggers (LCT). ...
(Date:7/29/2014)... Palm Beach, Florida (PRWEB) July 29, 2014 ... new scholarship for law students this week. The scholarship will ... of abused children and their families. , Steinger, Iscoe and ... past abuse, and want tomorrow’s attorneys to do the same. ... States each year according to the nonprofit Childhelp ...
Breaking Medicine News(10 mins):Health News:Cataract Surgery: New Technology for Reduced Dependence on Glasses 2Health News:'Love Hormone' Oxytocin May Help Some With Autism 2Health News:'Love Hormone' Oxytocin May Help Some With Autism 3Health News:Arthur Bruce Dental Helps College Students 2Health News:Steinger, Iscoe & Greene Offers Child Advocate Scholarship 2
... early studies into a new treatment for patients with ... an anti-depression 'pacemaker' found the electrical device can significantly ... pacemaker, which is implanted in a person's chest, sends ... brain. The device was originally used to treat patients ...
... Hyderabad, Andhra Pradesh chief minister Chandrababu Naidu has set ... City’ in the port town of Vishakhapatnam. By providing ... hopes to attract global pharmaceutical companies to the city ... by 2005. The ‘Pharma City’ will be developed by ...
... reduces the number of seizures suffered by severe epileptics, a ... coil which was placed on the side of the head ... ,The use of high-frequency pulses has been blamed for triggering ... using low-frequency magnetism.The ten patients in the Gottingen study suffered ...
... found six genes which may play a role in breast ... to gauge an individual woman's risk of developing cancer by ... breast cancer cases are currently thought to be caused by ... firmly linked with some cases of inherited breast cancer, but ...
... to a new study combining a diet rich in ... blood pressure, even in those not suffering from hypertension. ... lead to significant health benefits.// Previous research has shown ... levels of homocysteine, an amino acid linked to heart ...
... disorder which they say is responsible for people who find ... findings could lead to new treatments for jet lag//, insomnia ... Utah say people who cannot stay awake much after 8.30pm ... a disorder called "familial advanced sleep-phase syndrome". This means the ...
Cached Medicine News:
Quantitative determination of cortisol levels in serum and urine. Cross-reactivity with dexamethasone: 0.2% (suppression test).Time to first result: 30 minutes....
... IMMULITE 2000 assays are ... the IMMULITE 2000, a ... immunoassay analyzer. IMMULITE 2000 ... centralization, and a rapidly ...
... from KUBTEC is a dual capability system with ... representation of the specimen under test. While the ... images, the micro focus source also allows the ... standard 2D images. The 50 mm x 50 ...
... Provides Microsoft Windows-based urodynamics for fast, ... where logic, efficiency and economy are ... designed with modularity and expandability in ... diagnostic tools and establish a complete ...
Medicine Products: